Caruso said the period for the Remicade biosimilar ends early in October and there can be no launch before that. He added: “We will be vigorously defending our patent. Whether or not a ...

The US Food and Drug Administration has approved Celltrion's biosimilar of Johnson & Johnson's Remicade (infliximab) - but the launch date of the blockbuster's cheaper rival remains uncertain.

Experts explored the latest trends, approvals, and pipeline developments in cell and gene therapies, rare disease, immunology ...

The US Food and Drug Administration (FDA) has approved Celltrion USA’s Zymfentra (infliximab-dyyb) for the maintenance treatment of adults with moderately to severely active ulcerative colitis ...

Several of the top Branded Biologic Drugs along with their associated Biosimilar drugs include: Humira (Adalimumab); Remicade (Infliximab); Rituxan (Rituximab); Enbrel (Etanercept); Herceptin ...

Biosimilar adoption is hindered by complex reimbursement structures and misaligned incentives, despite their cost-saving potential. Collaborative stakeholder efforts and leveraging electronic ...

On Oct. 15, J&J JNJ announced strong third-quarter results, beating estimates for both earnings and sales. The Innovative ...

Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for blockbuster eye disease drug Eylea, the same judge has rejected the ...

In India, these drugs are underutilized due to high costs and limited awareness. Biosimilars offer a more affordable alternative. JAK inhibitors treat conditions like ankylosing spondylitis but ...

Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its blockbuster eye drug Eylea hit a legal roadblock. The judge ...

As a result of the deal, Blue Shield of California will purchase a Humira biosimilar for $525 per monthly dose, significantly below the drug’s net price of $2,100. The biosimilar will be availab ...